Sun Biomedical (ASX:SBN) Days Payable : 0.00 (As of Dec. 2023)

View and export this data going back to . Start your Free Trial

What is Sun Biomedical Days Payable?

Sun Biomedical's average Accounts Payable for the six months ended in Dec. 2023 was A$3.06 Mil. Sun Biomedical's Cost of Goods Sold for the six months ended in Dec. 2023 was A$0.00 Mil.

The historical rank and industry rank for Sun Biomedical's Days Payable or its related term are showing as below:

ASX:SBN's Days Payable is not ranked ^*
in the Biotechnology industry.
Industry Median: 148.28
* Ranked among companies with meaningful Days Payable only.

Sun Biomedical's Days Payable stayed the same from Dec. 2022 (0.00) to Dec. 2023 (0.00).

Sun Biomedical Days Payable Historical Data

The historical data trend for Sun Biomedical's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sun Biomedical Days Payable Chart

Sun Biomedical Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Days Payable

Get a 7-Day Free Trial

Sun Biomedical Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Days Payable	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Sun Biomedical's Days Payable

For the Biotechnology subindustry, Sun Biomedical's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sun Biomedical's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sun Biomedical's Days Payable distribution charts can be found below:

* The bar in red indicates where Sun Biomedical's Days Payable falls into.

Sun Biomedical Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Sun Biomedical's Days Payable for the fiscal year that ended in Jun. 2023 is calculated as

	Days Payable (A: Jun. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Jun. 2022 )	+	Accounts Payable (A: Jun. 2023 ))	/	count )	/	Cost of Goods Sold (A: Jun. 2023 )	*	Days in Period
=	( (1.111	+	5.137)	/	2 )	/	0	*	365
=	3.124					/	0	*	365
=	N/A

Sun Biomedical's Days Payable for the quarter that ended in Dec. 2023 is calculated as:

	Days Payable (Q: Dec. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Jun. 2023 )	+	Accounts Payable (Q: Dec. 2023 ))	/	count )	/	Cost of Goods Sold (Q: Dec. 2023 )	*	Days in Period
=	( (5.137	+	0.982)	/	2 )	/	0	*	365 / 2
=	3.0595					/	0	*	365 / 2
=	N/A

Sun Biomedical Days Payable Related Terms

Thank you for viewing the detailed overview of Sun Biomedical's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Sun Biomedical (ASX:SBN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sun Biomedical Ltd (ASX:SBN) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

DXB:Australia

Address

425 Smith Street, Fitzroy, VIC, AUS, 3065

Website

https://www.dimerix.com

Dimerix Ltd is a biopharmaceutical company developing innovative new therapies in areas with unmet medical needs. The company is developing five product candidates: DMX-200 for FSGS; DMX-200 for diabetic kidney disease; DMX-200 for COVID-19 pneumonia patients in ICU; DMX-200 for respiratory complications in Covid-19 patients; and DMX-700 for COPD; as well as the proprietary ReceptorHIT assay technology.

Sun Biomedical (ASX:SBN) Headlines

No Headlines